Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chihiro Endo-Tsukude"'
Autor:
Akihisa Kaneko, Chihiro Endo-Tsukude, Motohiro Kato, Shino Kuramoto, Masaki Ishigai, Akinobu Hamada, Satofumi Iida
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:325-333
By using the Relative Factor (RF) method-a method that can simply assess cytochrome P450 (CYP) induction risk based on a maximum induction effect model-we evaluated the risk of CYP2C9 induction and examined its relationship with risk of CYP3A4 induct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc51075349ee3ab7655ad61350d87287
https://doi.org/10.1016/j.dmpk.2019.07.002
https://doi.org/10.1016/j.dmpk.2019.07.002
Autor:
Kosuke Kashiwabara, Akinobu Hamada, Yuki Kai, Chihiro Endo-Tsukude, Yukari Tsubata, Mitsuhiro Hayashi, Hideyuki Saito, Hirotsugu Kohrogi, Jiichiro Sasaki, Sho Saeki, Shinji Fujii, Sunao Ushijima, Hiroto Kishi, Megumi Inaba, Hiroshi Semba, Norihiro Iwamoto, Takeshi Isobe
Publikováno v:
Biological & Pharmaceutical Bulletin. 41:47-56
Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese non-small-cell lung cancer patients treated with oral erlotinib at a standard dose of 150 mg aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad494d53e885f53fe8ade834bbc85d6c
https://doi.org/10.1248/bpb.b17-00521
https://doi.org/10.1248/bpb.b17-00521
Autor:
Katherine L. Gill, Iain Gardner, Neil Parrott, Chihiro Endo-Tsukude, Kimio Terao, Oliver Hatley, Patricia Sanwald Ducray, Krishna K. Machavaram
Publikováno v:
The AAPS Journal. 21
A physiologically based pharmacokinetic (PBPK) model was used to simulate the impact of elevated levels of interleukin (IL)-6 on the exposure of several orally administered cytochrome P450 (CYP) probe substrates (caffeine, S-warfarin, omeprazole, dex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f475909d3cf4e142ce5e4f4bc2a47d5
https://doi.org/10.1208/s12248-019-0309-y
https://doi.org/10.1208/s12248-019-0309-y
Autor:
Chihiro Endo-Tsukude, Toshihiko Doi, Yutaka Fujiwara, Satoru Iwasa, Nobuaki Matsubara, Junichi Tomomatsu, Shintaro Nakagawa, Shunji Takahashi, Akari Tanaka
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6793e6fb2369a3d9c77159923253d200
https://pubmed.ncbi.nlm.nih.gov/31227862
https://pubmed.ncbi.nlm.nih.gov/31227862
Autor:
Sunao Ushijima, Kosuke Kashiwabara, Hiroshi Semba, Hirotsugu Kohrogi, Akinobu Hamada, Sho Saeki, Jiichiro Sasaki, Takeshi Isobe, Shinji Fujii, Yuki Kai, Yukari Tsubata, Norihiro Iwamoto, Hideyuki Saito, Hiroto Kishi, Chihiro Endo-Tsukude, Megumi Inaba
Publikováno v:
Cancer Research. 75:5481-5481
Introduction: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor, a 150 mg daily dose of which has been shown to be effective for improving overall survival in non-small-cell lung cancer (NSCLC) patients who had failed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0978870850d13f99b11cbc78e52d5676
https://doi.org/10.1158/1538-7445.am2015-5481
https://doi.org/10.1158/1538-7445.am2015-5481